Ignite Creation Date:
2024-05-06 @ 2:59 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04481113
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-07
First Post:
2020-07-17
Brief Title:
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
Sponsor:
OHSU Knight Cancer Institute
Organization:
OHSU Knight Cancer Institute
Organization Data
Organization:
OHSU Knight Cancer Institute
Class:
OTHER
Study ID:
STUDY00021243
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
OHSU Knight Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Alexandra Zimmer
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
OHSU Knight Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Oregon Health and Science University | OTHER |
| Eli Lilly and Company | INDUSTRY |
| GlaxoSmithKline | INDUSTRY |